Literature DB >> 20146339

Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age.

Haruko Shima1, Masashi Miharu, Tomoo Osumi, Takao Takahashi, Hiroyuki Shimada.   

Abstract

The relationship between trough plasma concentrations and daily doses of voriconazole was retrospectively analyzed in < or = 18-year-old children because optimal oral voriconazole dosages for children, especially <2 years of age, is unknown. We demonstrated that the relationship changed around the age of 3 years, and that children <3 years of age required higher optimal daily doses with greater variations compared with those for older children, resulting in complicated optimal dose adjustments. Therefore, plasma concentration monitoring and individual dose adjustments are recommended for optimal and less toxic voriconazole treatments, especially for <3-year-old children, although additional studies are needed to validate this approach. Copyright 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20146339     DOI: 10.1002/pbc.22451

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  10 in total

1.  Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.

Authors:  Elizabeth H Doby; Daniel K Benjamin; Anne J Blaschke; Robert M Ward; Andrew T Pavia; Paul L Martin; Timothy A Driscoll; Michael Cohen-Wolkowiez; Cassandra Moran
Journal:  Pediatr Infect Dis J       Date:  2012-06       Impact factor: 2.129

2.  A phase I dose finding study of intravenous voriconazole in pediatric patients undergoing hematopoietic cell transplantation.

Authors:  Jessica Knight-Perry; Cathryn Jennissen; Susie E Long; Stefanie Hage; Todd E DeFor; Wing T Chan; James Fisher; Mark N Kirstein; Angela R Smith
Journal:  Bone Marrow Transplant       Date:  2019-11-25       Impact factor: 5.483

Review 3.  Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data.

Authors:  Christopher C Dvorak; Brian T Fisher; Lillian Sung; William J Steinbach; Michael Nieder; Sarah Alexander; Theoklis E Zaoutis
Journal:  Pediatr Blood Cancer       Date:  2011-11-18       Impact factor: 3.167

4.  Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.

Authors:  J Kevin Hicks; Kristine R Crews; Patricia Flynn; Cyrine E Haidar; Calvin C Daniels; Wenjian Yang; John C Panetta; Deqing Pei; Jeffrey R Scott; Alejandro R Molinelli; Ulrich Broeckel; Deepa Bhojwani; William E Evans; Mary V Relling
Journal:  Pharmacogenomics       Date:  2014-06       Impact factor: 2.533

Review 5.  Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.

Authors:  Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

Review 6.  Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.

Authors:  Chris Stockmann; Jonathan E Constance; Jessica K Roberts; Jared Olson; Elizabeth H Doby; Krow Ampofo; Justin Stiers; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

7.  Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.

Authors:  Imke H Bartelink; Tom Wolfs; Martine Jonker; Marjolein de Waal; Toine C G Egberts; Tessa T Ververs; Jaap J Boelens; Marc Bierings
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

Review 8.  The use of antifungal therapy in neonatal intensive care.

Authors:  Daniela Testoni; P Brian Smith; Daniel K Benjamin
Journal:  Clin Perinatol       Date:  2012-01-11       Impact factor: 2.642

9.  Pharmacogenetic Analysis of Voriconazole Treatment in Children.

Authors:  Romy Tilen; Paolo Paioni; Aljoscha N Goetschi; Roland Goers; Isabell Seibert; Daniel Müller; Julia A Bielicki; Christoph Berger; Stefanie D Krämer; Henriette E Meyer Zu Schwabedissen
Journal:  Pharmaceutics       Date:  2022-06-17       Impact factor: 6.525

10.  CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation.

Authors:  Takuto Takahashi; Maryam A Mohamud; Angela R Smith; Pamala A Jacobson; Mutaz M Jaber; Abeer F Alharbi; James Fisher; Mark N Kirstein
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.